TITLE

HIV market: collaborative combinations

PUB. DATE
April 2007
SOURCE
PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p25
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article presents analyzes the competition between several pharmaceutical companies that develop HIV drugs. The companies Tibotec and Gilead Inc., that are launching new HIV drugs, TMC278 and elvitegravir respectively, are expected to compete with Bristol-Myers Squibb Co.'s Sustiva, and Merck & Co. Inc.'s MK0518. It is suggested that these companies should plan to make collaborative efforts to improve their drug quality and to perform well against more established competitors.
ACCESSION #
25067848

 

Related Articles

  • Key Infectious Announcements, May 15, 2004 -- June 14, 2004.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p23 

    Reports developments in pharmaceutical industry in the U.S. as of June 14, 2004. Plans of Bristol-Myers Squibb Co., Gilead Sciences Inc. and Merck & Co. Inc. to co-develop combination HIV medicine; Reaction of the World Health Organization to the U.S. Government's announcement of its expedited...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p23 

    Reports developments in pharmaceutical industry in the U.S. as of July 2004. Plans of Bristol-Myers Squibb Co., Gilead Sciences Inc. and Merck & Co. Inc. to co-develop combination HIV medicine; Reaction of the World Health Organization to the U.S. Government's announcement of its expedited...

  • Other News To Note.  // BioWorld Today;12/5/2011, Vol. 22 Issue 234, p2 

    This section offers news briefs on the pharmaceutical industry. A deal is signed by Bristol-Myers Squibb Co. with Tibotec Pharmaceuticals to evaluate the use of declatasvir NS5A replication complex inhibitor. A financial restructuring will be implemented by Northwest Biotherapeutics Inc....

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;December2004, Vol. 3 Issue 12, p24 

    Reports on developments related to the pharmaceutical industry. Comparison of the efficacy of Bristol-Myers Squibb Co.'s hepatitis drug with GlaxoSmithKline PLC in clinical trials; Research programs received by Gilead Sciences Inc.; Efforts of the U.S. government to expand flu vaccine supplies.

  • Big Pharma Ramps Up Hep C Strategies. AMY REEVES // Investors Business Daily;3/20/2014, pA01 

    Though still in the early days since its Dec. 6 approval, Gilead Sciences' hepatitis C drug Sovaldi may be enjoying one of the most massive drug launches of all time. Current consensus calls for sales of $4.6 billion this year — and the whisper numbers are running even higher.

  • Vertex Not A Good Fit For Gilead, Says Piper Jaffray. AMY REEVES // Investors Business Daily;9/18/2015, p00 

    The article reports on the claim of investment bank and asset management firm Piper Jaffray and Co. that pharmaceutical companies Incyte Corp. or Bristol-Myers Squibb Co. will serve as perfect business partner of American biotechnology company Gilead Sciences Inc.

  • Drug makers putting complete AIDS treatment in one daily pill.  // Gay & Lesbian Times;12/30/2004, Issue 888, p26 

    Reports that AIDS drug makers Bristol-Myers Squibb Co. and Gilead Sciences Inc. have formed a joint venture to test and market a single pill combining widely used medicines. Components of the combination pill; Functions; Cost of the drugs.

  • CORPORATE.  // MondayMorning;7/27/2009, Vol. 17 Issue 28, p2 

    The article offers news briefs from the pharmaceutical industry in the U.S. The second quarter earnings posted by Bristol-Myers Squibb Co., New York and Wyeth, Madison, New Jersey, have topped expectations in an otherwise bleak economic scenario. The quarterly profit of Gilead Sciences Inc. has...

  • HIV Treatment in One Daily Pill.  // Guide;Feb2005, Vol. 25 Issue 2, p78 

    Reports on drug firms Bristol-Myers Squibb Co. and Gilead Sciences Inc.'s formation of a joint venture to manufacture and test the once-daily pill containing AIDS medicines Sustiva, Viread and Emtriva.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics